Abstract
Background aims
Third party virus-specific T cells (VST) has shown efficacy for opportunistic virus
infection which do not have effective treatment or are drug-refractory. We describe
our preparatory work in setting up a third-party VST bank for a multi-ethnic Asian
population.
Methods
Discarded white cells from regular blood bank plateletpheresis donors with known locally
prevalent HLA antigens were cultured in small scale to generate VST against Adenovirus,
BK virus, Cytomegalovirus, Epstein–Barr virus, and Human Herpes Virus 6. Multi-virus
specific T cells (multi-VST) were also generated against all 5 viruses in single cultures.
A strategy of allelic typing for donors with good and broad-spectrum cytotoxicity
together with consideration on HLA restriction for the virus epitope was used to select
combinations of VST lines for a hypothetical third party VST bank. The breadth of
coverage based on these selection criteria was validated using our database of 100
post haematopoietic stem cell transplant patients.
Results
We show that 50%, 42%, 56%, 56% and 42% of single VST cultures demonstrated specific
cytotoxicity against AdV, BKV, CMV, EBV and HHV6 respectively. Twenty four of the
36 multi-VST lines showed activity against at least 2 of the 5 viruses studied. A
carefully selected combination of just 6 VST lines can offer VST with at least 1 allelic
match to 99% of potential recipients, while 92% can find 2 allelic matches and 79%
can find 3 allelic matches.
Conclusions
This preparatory work confirms that a cost-effective strategy recruiting a small number
of pre-characterized donors can generate VST lines with broad coverage for a multi-ethnic
Asian patient population, thereby laying the foundation for setting up of a third
party VST bank for Asian patients.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.Blood. 2010; 115: 925-935
- Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.Blood. 2013; 121: 5113-5123
- Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.J Clin Oncol. 2017; 35: 3547-3557
- Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.Blood. 2007; 110: 1123-1131
- Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.Br J Haematol. 2014; 167: 402-410
- Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction.Bone Marrow Transplant. 2019; 54: 759-764
- Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.Blood advances. 2017; 1: 2193-2205
- Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program.Biol Blood Marrow Transplant. 2018; 24: 2433-2442
- Population-specific recombination sites within the human MHC region.Heredity. 2013; 111: 131-138
- Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.Mol Ther. 2012; 20: 1622-1632
- Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.Science translational medicine. 2014; 6: 242ra83
- Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.Blood advances. 2020; 4: 5745-5754
- A novel simplified method of generating cytomegalovirus-specific cytokine-induced killer cells of high specificity and superior potency with GMP compliance.Clin Immunol. 2019; 205: 83-92
- Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.Lancet (London, England). 2002; 360: 436-442
- "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients.Blood advances. 2019; 3: 2571-2580
- CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.Biol Blood Marrow Transplant. 2013; 19: 1480-1492
- Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients.J Clin Immunol. 2022; 42: 546-558
Article info
Publication history
Published online: March 06, 2023
Accepted:
February 4,
2023
Received:
September 26,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
